Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

Cardiovascular Diabetology
N J TripoltH Sourij

Abstract

Early glucose lowering intervention in subjects with type 2 diabetes mellitus was demonstrated to be beneficial in terms of micro- and macrovascular risk reduction. However, most of currently ongoing cardiovascular outcome trials are performed in subjects with manifest atherosclerosis and long-standing diabetes. Therefore, the aim of this study is to investigate the effects of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM) on a set of cardiovascular surrogate measurements. In this randomized, placebo-controlled, double-blind, single-center study, we included subjects with early diabetes (postchallenge diabetes (2 h glucose > 200 mg/dl) or T2DM treated with diet only or on a stable dose of metformin monotherapy and an HbA1c < 75 mmol/mol) and established CAD. Participants were randomized to receive either linagliptin (5 mg) once daily orally or placebo for 12 weeks. The primary outcome was the change in flow mediated dilatation (FMD). The secondary objective was to investigate the effect of linagliptin treatment on arginine bioavailability ratios [Global arginine bioavailability ratio (GABR) and arginine to ornithine ratio (AOR)]. Arginine,...Continue Reading

Associated Clinical Trials

References

Oct 5, 2010·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Jun Seita, Irving L Weissman
Sep 17, 2011·Current Pharmaceutical Design·Dirk Strunk
Jul 19, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·N J TripoltH Sourij
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Mar 18, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nikolaus MarxHans-Juergen Woerle
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 15, 2016·Cardiovascular Diabetology·Tatsuya MaruhashiUNKNOWN PROLOGUE Study Investigators
Mar 7, 2017·Nature Reviews. Nephrology·Berthold Hocher, Jerzy Adamski
Apr 20, 2017·Journal of Molecular Endocrinology·Ahmed A Hasan, Berthold Hocher

❮ Previous
Next ❯

Citations

Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Mar 2, 2019·Cardiovascular Diabetology·Atsushi Tanaka, Koichi Node

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT01897532
NCT02350478

Software Mentioned

Randomizer for
CARMELINA
SAS

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.